✉ Email this page to a colleague
« Back to Dashboard
Bimagrumab is an investigational drug.
There have been 7 clinical trials for Bimagrumab. The most recent clinical trial was a Phase 3 trial, which was initiated on November 2nd 2015.
The most common disease conditions in clinical trials are Myositis, Inclusion Body, Myositis, and Sarcopenia. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are two US patents protecting this investigational drug and eighteen international patents.
Recent Clinical Trials for Bimagrumab
|Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes||Novartis Pharmaceuticals||Phase 2|
|An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203||Novartis Pharmaceuticals||Phase 3|
|A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study||Novartis Pharmaceuticals||Phase 2|
Top disease conditions for Bimagrumab
Top clinical trial sponsors for Bimagrumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Bimagrumab||See Plans and Pricing||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||See Plans and Pricing|
|Bimagrumab||See Plans and Pricing||Administration of bimagrumab for improving muscle mass and function after hip fracture surgery||Novartis AG (Basel, CH)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Bimagrumab||Australia||AU2015249396||2034-04-24||See Plans and Pricing|
|Bimagrumab||Australia||AU2018200537||2034-04-24||See Plans and Pricing|
|Bimagrumab||Brazil||BR112016023979||2034-04-24||See Plans and Pricing|
|Bimagrumab||Canada||CA2944842||2034-04-24||See Plans and Pricing|
|Bimagrumab||Chile||CL2016002679||2034-04-24||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|